Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONS-5010 vs Ranibizumab in Wet AMD (NORSE EIGHT)
NCT06190093Phase 3Completed
- Sponsor
- Outlook Therapeutics
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab-vikg in neovascular age-related macular degeneration (NVAMD), sponsored by Outlook Therapeutics. Started Jan 2024; status: completed.
02
Drugs
bevacizumab-vikg
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06190093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190093.